Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment
We describe the molecular cues and corresponding intervention methods, collate several promising targets and progress worthy of further study, and put forward the importance of integrated immunotherapy to provide ideas for future research of TME and immunotherapy of PDAC. (Source: Cellular Oncology)
Source: Cellular Oncology - November 11, 2022 Category: Cancer & Oncology Source Type: research
PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity
ConclusionThis work reveals the anti-tumor effect of PKMYT1 in LUAD and provides evidence to clarify the dual roles of PKMYT1 in tumor progression. Moreover, our findings broaden the current understandings on AKT1 activation and identify PKMYT1 as a potential negative regulator of AKT1 kinase activity, providing further insights into targeting the AKT pathway in LUAD. (Source: Cellular Oncology)
Source: Cellular Oncology - November 9, 2022 Category: Cancer & Oncology Source Type: research
Correction to: ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis
(Source: Cellular Oncology)
Source: Cellular Oncology - November 9, 2022 Category: Cancer & Oncology Source Type: research
FUT8 is regulated by miR ‐122‐5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling
ConclusionsThese findings demonstrated that FUT8, regulated by miR ‐122‐5p, could be a tumor promoter of iCCA through PI3K/AKT signaling pathway. (Source: Cellular Oncology)
Source: Cellular Oncology - November 8, 2022 Category: Cancer & Oncology Source Type: research
Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin
ConclusionWe suggest that myriocin is a novel potent anti-cancer agent that dually targets both VEGFR2 in ECs and I κBα in cancer cells, and exerts more pronounced anti-tumor effects than with either kinase being inhibited alone. (Source: Cellular Oncology)
Source: Cellular Oncology - November 4, 2022 Category: Cancer & Oncology Source Type: research
ITGA2 induces STING expression in pancreatic cancer by inducing DNMT1 degradation
ConclusionOur data indicate that ITGA2 induces STING expression by interacting with DNMT1 and inducing the degradation of DNMT1. ITGA2 silencing combined with DNMT1 inhibitor treatment may be a novel therapeutic strategy for pancreatic cancer. (Source: Cellular Oncology)
Source: Cellular Oncology - November 4, 2022 Category: Cancer & Oncology Source Type: research
Role of nerves in neurofibromatosis type 1-related nervous system tumors
ConclusionIn this review, we summarize existing evidence about the specific effects ofNF1 mutation on neurons and emerging research on the role of nerves in neurological tumor development, promising a new set of selective and targeted therapies for NF1-related tumors. (Source: Cellular Oncology)
Source: Cellular Oncology - November 3, 2022 Category: Cancer & Oncology Source Type: research
DNASE1L3 inhibits hepatocellular carcinoma by delaying cell cycle progression through CDK2
ConclusionOur study unveils DNASE1L3 as a novel HCC cell cycle regulator and tumor suppressor. DNASE1L3 impairs HCC tumorigenesis by delaying cell cycle progression possibly through disrupting the positive E2F1-CDK2 regulatory loop. DNASE1L3 may serve as a target for the development of novel therapeutic strategies against HCC. (Source: Cellular Oncology)
Source: Cellular Oncology - November 3, 2022 Category: Cancer & Oncology Source Type: research
CoQ10 reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation
ConclusionsCoQ10 has a pleiotropic effect on GBM growth, targeting several hallmarks simultaneously. Thus, its integration into current treatments of this fatal disease should be considered. (Source: Cellular Oncology)
Source: Cellular Oncology - November 2, 2022 Category: Cancer & Oncology Source Type: research
Research advances and treatment perspectives of pancreatic adenosquamous carcinoma
ConclusionThe present paper systematically summarizes the possible pathogenesis, diagnosis methods, and further suggests potential new treatment directions through reviewing research results of PASC, including the clinical manifestations, pathological manifestation, the original hypothesis of squamous carcinoma and the potential regulatory mechanism. In short, the present paper provides a systematic review of the research progress and new ideas for the development mechanism and treatment of PASC. (Source: Cellular Oncology)
Source: Cellular Oncology - November 1, 2022 Category: Cancer & Oncology Source Type: research
In vivo study revealed pro-tumorigenic effect of CMTM3 in hepatocellular carcinoma involving the regulation of peroxisome proliferator-activated receptor gamma (PPAR γ)
ConclusionThis study clarified the pro-tumorigenesis role of CMTM3 in HCCin vivo, possibly through the upregulation of PPAR γ and activation of the PPAR pathway.Graphical abstract (Source: Cellular Oncology)
Source: Cellular Oncology - October 26, 2022 Category: Cancer & Oncology Source Type: research
Distinct expression and function of breast cancer metastasis suppressor 1 in mutant P53 glioblastoma
ConclusionOur data indicate upregulation of BRMS1 in high grade astrocytomas which correlates positively withmutant P53 and a poor patient survival. Silencing of BRMS1 inmutant P53 GBM cell lines resulted in a reduced cellular growth and migration/invasion by suppressing the EGFR-AKT/NF-kB signaling pathway. BRMS1 may serve as a predictive biomarker and therapeutic target inmutant P53 GBM. (Source: Cellular Oncology)
Source: Cellular Oncology - October 26, 2022 Category: Cancer & Oncology Source Type: research
Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy
ConclusionsThe newly established GEP-NET and GEP-NEC cell lines represent comprehensive preclinical in vitro models suitable to decipher GEP-NEN biology and pathogenesis. Additionally, we present the first results of a GEP-NEN-specific mutation-based targeted therapy. These findings open up new potentialities for personalized therapies in GEP-NEN. (Source: Cellular Oncology)
Source: Cellular Oncology - October 21, 2022 Category: Cancer & Oncology Source Type: research
Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8+T cells
ConclusionLow-dose anti-VEGFR2 antibody combined with anti-PD1 antibody therapy promoted anti-tumor immunity and the downregulation of LAYN in tumor-infiltrating CD8+T cells played an important role in this process. These findings had implications for improving the efficacy of immune checkpoint blockade therapy and further optimized clinical treatment guidelines in advanced LUAD. (Source: Cellular Oncology)
Source: Cellular Oncology - October 19, 2022 Category: Cancer & Oncology Source Type: research
Distinct tumor microenvironment landscapes of rectal cancer for prognosis and prediction of immunotherapy response
ConclusionsWe identified four TME-based RC subtypes with distinct biological and clinical features. Based on those subtypes, we also proposed a degenerated 10-gene signature to predict the prognosis and immunotherapy response. (Source: Cellular Oncology)
Source: Cellular Oncology - October 17, 2022 Category: Cancer & Oncology Source Type: research
